The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10146 malaria professionals are enjoying the free benefits of MalariaWorld today

malaria vaccine

Production, Quality Control, Stability and Pharmacotoxicity of a Malaria Vaccine Comprising Three Highly Similar PfAMA1 Protein Molecules to Overcome Antigenic Variation

October 11, 2016 - 17:32 -- Open Access
Author(s): 
Bart W. Faber, Stephan Hellwig, Edmond J. Remarque, et al.
Reference: 
PLoS ONE 11(10): e0164053

Plasmodium falciparum apical membrane antigen 1 (PfAMA1) is a leading asexual blood stage vaccine candidate for malaria.

Medical Treatment: 

The Influence of Sub-Unit Composition and Expression System on the Functional Antibody Response in the Development of a VAR2CSA Based Plasmodium falciparum Placental Malaria Vaccine

September 8, 2015 - 15:49 -- Open Access
Author(s): 
Morten A. Nielsen, Mafalda Resende, Ali Salanti, et al.
Reference: 
PLoS ONE 10(9): e0135406

The disease caused by Plasmodium falciparum (Pf) involves different clinical manifestations that, cumulatively, kill hundreds of thousands every year.

Medical Treatment: 

Robust, reproducible, industrialized, standard membrane feeding assay for assessing the transmission blocking activity of vaccines and drugs against Plasmodium falciparum

April 15, 2015 - 05:28 -- Open Access
Tags: 
Author(s): 
Li T, Eappen AG, Richman AM, Billingsley PF, Abebe Y, Li M, Padilla D, Rodriguez-Barraquer I, Sim B, Hoffman SL
Reference: 
Malaria Journal 2015, 14 :150 (9 April 2015)

These results demonstrate a robust capacity to perform the SMFA in a medium-to-high throughput format, suitable for assessing large numbers of experimental samples of candidate antibodies or drugs.

Medical Treatment: 

Calibration of an intrahost malaria model and parameter ensemble evaluation of a pre-erythrocytic vaccine

January 12, 2015 - 14:46 -- Open Access
Tags: 
Author(s): 
Kevin A McCarthy, Edward A Wenger, Grace H Huynh, Philip A Eckhoff
Reference: 
Malaria Journal 2015, 14:6 (7 January 2015)

Roll-out of routine immunization with pre-erythrocytic malaria vaccines can provide substantial burden reduction across a range of transmission conditions typical to many regions in Africa.

Continent: 
Medical Treatment: 

Acceptance of a malaria vaccine by caregivers of sick children in Kenya

May 14, 2014 - 12:18 -- Open Access
Tags: 
Author(s): 
Ojakaa DI, Jarvis JD, Matilu MI, Thiam S
Reference: 
Malaria Journal 2014, 13 :172 (5 May 2014)

Results from this study indicate a need for targeted messages and education on a malaria vaccine, particularly for residents of regions where acceptance is low, older caregivers, and those with low literacy and school-attendance levels.

Country: 
Medical Treatment: 

NOT Open Access | Tricomponent Complex Loaded with a Mosquito-Stage Antigen of the Malaria Parasite Induces Potent Transmission-Blocking Immunity

April 1, 2014 - 09:40 -- NOT Open Access
Tags: 
Author(s): 
Takeshi Arakawa, Takafumi Tsuboi, Jetsumon Sattabongkot, Kozue Sakao, Motomi Torii, and Takeshi Miyata
Reference: 
Clin Vaccine Immunol April 2014 vol. 21 no. 4 561-569

The development of malaria vaccines is challenging, partly because the immunogenicity of recombinant malaria parasite antigens is low.

Medical Treatment: 

Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS,S/AS02D malaria vaccine in infants living in a malaria-endemic region

January 13, 2013 - 13:48 -- Open Access
Author(s): 
Abdulla S, Salim N, Tanner M, et al.
Reference: 
Malaria Journal 2013, 12:11 (8 January 2013)
MalariaWorld

Safety, immunogenicity and efficacy of the RTS,S/AS02D vaccine candidate when integrated into a standard EPI schedule for infants have been reported over a nine-month surveillance period. This paper describes results following 20 months of follow up.

Person: 
Medical Treatment: 

Not Open Access | Review: Development of a virosomal malaria vaccine candidate: from synthetic peptide design to clinical concept validation

August 27, 2012 - 14:54 -- Patrick Sampao
Author(s): 
Gerd Pluschke & Marco Tamborrini
Reference: 
Future Virology, August 2012, Vol. 7, No. 8, Pages 779-790

MalariaWorldIn this review, we summarize and discuss a strategy to develop synthetic peptidomimetics of key malaria target antigens for inclusion in a multivalent malaria subunit vaccine based on immunopotentiating reconstituted influenza virosomes.

Technology: 
Medical Treatment: 

Open Access | Evidence for erythrocyte-binding antigen 175 as a component of a ligand-blocking blood-stage malaria vaccine

May 5, 2011 - 06:29 -- Kabogo Ndegwa
Author(s): 
Lubin Jiang, Deepak Gaur, Jianbing Mu, Hong Zhou, Carole A. Long, and Louis H. Miller
Reference: 
PNAS May 3, 2011 vol. 108 no. 18 7553-7558

The ligands that pathogens use to invade their target cells have often proven to be good targets for vaccine development.

Medical Condition: 
Medical Treatment: 

Pages

Subscribe to RSS - malaria vaccine